[{"id":"00f2945d-93f1-4243-9713-50b181253dce","acronym":"NCI-2018-02699","url":"https://clinicaltrials.gov/study/NCT03749018","created_at":"2021-01-18T18:23:00.454Z","updated_at":"2025-02-25T14:27:50.683Z","phase":"Phase 2","brief_title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT03749018 - NCI-2018-02699","lead_sponsor":"David Bond, MD","biomarkers":" PD-L1 • BCL2 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • BCL2 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-11-04"},{"id":"59201174-86d0-4c21-b519-220173f5e9be","acronym":"ENABLE","url":"https://clinicaltrials.gov/study/NCT04049513","created_at":"2021-01-18T19:51:32.910Z","updated_at":"2024-07-02T16:34:26.420Z","phase":"Phase 1","brief_title":"ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)","source_id_and_acronym":"NCT04049513 - ENABLE","lead_sponsor":"Malaghan Institute of Medical Research","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • WZTL-002 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/11/2019","start_date":" 10/11/2019","primary_txt":" Primary completion: 06/12/2024","primary_completion_date":" 06/12/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"92a6a0af-b961-4dcd-9f55-a9a03ecbdb52","acronym":"TRANSCEND-NHL-001","url":"https://clinicaltrials.gov/study/NCT02631044","created_at":"2021-01-17T17:40:23.377Z","updated_at":"2024-07-02T16:35:12.562Z","phase":"Phase 1","brief_title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","source_id_and_acronym":"NCT02631044 - TRANSCEND-NHL-001","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 387","initiation":"Initiation: 01/06/2016","start_date":" 01/06/2016","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 05/10/2024","study_completion_date":" 05/10/2024","last_update_posted":"2024-03-27"},{"id":"d66d264b-f1b4-4b9d-a8e5-a0062a91f59e","acronym":"O-ICE","url":"https://clinicaltrials.gov/study/NCT02393157","created_at":"2021-01-18T11:24:47.737Z","updated_at":"2024-07-02T16:35:31.507Z","phase":"Phase 2","brief_title":"Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","source_id_and_acronym":"NCT02393157 - O-ICE","lead_sponsor":"New York Medical College","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/21/2015","start_date":" 08/21/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-26"},{"id":"8a4f4c76-2dc0-425a-a17a-009310b1b1fb","acronym":"IELSG37","url":"https://clinicaltrials.gov/study/NCT01599559","created_at":"2021-01-18T06:50:23.394Z","updated_at":"2024-07-02T16:35:32.505Z","phase":"Phase 3","brief_title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","source_id_and_acronym":"NCT01599559 - IELSG37","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 12/17/2029","study_completion_date":" 12/17/2029","last_update_posted":"2023-10-19"},{"id":"4608c564-d9e9-4ab5-91b3-70a26ad8628a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924326","created_at":"2021-01-18T03:34:48.192Z","updated_at":"2024-07-02T16:36:18.533Z","phase":"Phase 1/2","brief_title":"CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma","source_id_and_acronym":"NCT00924326","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/17/2009","start_date":" 02/17/2009","primary_txt":" Primary completion: 09/30/2015","primary_completion_date":" 09/30/2015","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2022-01-12"},{"id":"1ee14a8c-efd9-437b-9c85-2db798cb4018","acronym":"KEYNOTE-013","url":"https://clinicaltrials.gov/study/NCT01953692","created_at":"2021-07-12T21:52:50.778Z","updated_at":"2024-07-02T16:36:26.919Z","phase":"Phase 1","brief_title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","source_id_and_acronym":"NCT01953692 - KEYNOTE-013","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 197","initiation":"Initiation: 11/22/2013","start_date":" 11/22/2013","primary_txt":" Primary completion: 06/26/2020","primary_completion_date":" 06/26/2020","study_txt":" Completion: 06/26/2020","study_completion_date":" 06/26/2020","last_update_posted":"2021-08-04"},{"id":"08d3cf7e-53db-4d97-bd5c-e37278f8ab16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04787263","created_at":"2021-03-08T12:53:53.051Z","updated_at":"2024-07-02T16:36:32.763Z","phase":"Phase 1/2","brief_title":"CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML","source_id_and_acronym":"NCT04787263","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" TP53 • CD19 • TCF3 • PBX1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD19 expression","tags":["TP53 • CD19 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-CAR_Lenti T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2038","study_completion_date":" 03/03/2038","last_update_posted":"2021-03-26"},{"id":"6018f2e9-3ee9-46ff-8c88-8f6cfcbdaba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00944567","created_at":"2021-01-18T03:40:08.242Z","updated_at":"2024-07-02T16:37:18.871Z","phase":"","brief_title":"A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma","source_id_and_acronym":"NCT00944567","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 02/27/2017","study_completion_date":" 02/27/2017","last_update_posted":"2017-08-15"}]